Benzylamine → HCID 59593076, compound

HRID 2098725Notes

Reaction equation

HRID 2098725 reaction equation
[NH:1]1[C:9]2[C:4](=[C:5]([C:10]3[N:11]=[C:12]([N:22]4[CH2:27][CH2:26][O:25][CH2:24][CH2:23]4)[C:13]4[S:18][C:17]([C:19](O)=[O:20])=[CH:16][C:14]=4[N:15]=3)[CH:6]=[CH:7][CH:8]=2)[CH:3]=[N:2]1.[CH2:28]([NH2:35])[C:29]1[CH:34]=[CH:33][CH:32]=[CH:31][CH:30]=1>>[CH2:28]([NH:35][C:19]([C:17]1[S:18][C:13]2[C:12]([N:22]3[CH2:27][CH2:26][O:25][CH2:24][CH2:23]3)=[N:11][C:10]([C:5]3[CH:6]=[CH:7][CH:8]=[C:9]4[C:4]=3[CH:3]=[N:2][NH:1]4)=[N:15][C:14]=2[CH:16]=1)=[O:20])[C:29]1[CH:34]=[CH:33][CH:32]=[CH:31][CH:30]=1

Participants

3

Reactant 2

HCID 7504BenzylamineHCID 595931412-(1H-Indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidine-6-carboxylic acid

Product 1

HCID 59593076HCID 59593076, compound

Procedure

2-(1H-Indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidine-6-carboxylic acid 13 (30 mg) was coupled to benzylamine via General Procedure B. The product was purified via reverse phase HPLC to give 8.9 mg of 245. MS (Q1) 470.8 (M)+

Workup

  1. customThe product was purified via reverse phase HPLC

Sources & evidence

ORD record
ord-a3e16a9064654b2ca39c93498bd42b60
Source dataset
uspto-grants-2013_05
Patent number
US08450315B2

Reaction notes

Loading…